Q: What is Enspryng used for?

Enspryng is used to treat neuromyelitis optica spectrum disorder .

Q: How does Enspryng work?

Mechanism of Action Enspryng belongs to a class of drugs known as interleukin-6 (IL-6) receptor antagonists. It is a laboratory-made protein called a monoclonal antibody that is designed to recognize and attach to a specific target in the body. The target for Enspryng is the IL-6 receptor. IL-6 is a naturally occurring protein that acts as a chemical messenger in the immune system. While IL-6 helps the body fight infections, having too much of it can lead to excessive inflammation and cause the immune system to attack the body's own healthy tissues. Reducing Immune Attacks In neuromyelitis optica spectrum disorder (NMOSD), the immune system attacks the optic nerves and the spinal cord. This often involves the production of harmful antibodies and significant inflammation. By blocking the IL-6 receptor, Enspryng prevents the IL-6 protein from triggering these inflammatory responses. This process helps to: Limit inflammation in the central nervous system. Reduce the activity of immune cells that contribute to nerve damage. Lower the frequency of disease relapses or attacks. Enspryng is used specifically in adults who have a certain type of NMOSD where the body produces antibodies against a protein called aquaporin-4 (AQP4).

Q: What are the active ingredients in Enspryng?

The active ingredient in Enspryng is satralizumab .

Q: What are the side effects of Enspryng?

Common side effects of Enspryng may include: upper respiratory tract infection headache joint pain Always consult with a healthcare professional about potential side effects.

Q: What drug class is Enspryng?

Enspryng belongs to the IL-6 receptor antagonist drug class.

Q: What is the dosage of Enspryng and how do I take it?

Administration Method Enspryng is given as a subcutaneous injection, which means it is injected into the fatty tissue just under the skin. The injection is usually administered in the abdomen or the thigh. It is important to rotate the injection site with each dose and avoid areas where the skin is tender, bruised, red, or hard. General Dosing Pattern The treatment schedule generally begins with a loading phase, where several initial doses are given at specific intervals. After this initial phase is complete, the medication is transitioned to a maintenance schedule where it is administered at regular intervals to help manage the condition. Self-Injection and Preparation A healthcare provider may train a patient or caregiver to administer the injection at home. Before use, the medication should be removed from the refrigerator and allowed to reach room temperature naturally. The solution should be inspected for particles or discoloration before injecting, and the syringe should not be shaken. Missed Doses If a dose is missed, it should be administered as soon as possible. Do not wait until the next scheduled dose is due. Once the missed dose is taken, the regular dosing schedule should be resumed based on that new timing.

Q: Is Enspryng safe during pregnancy and breastfeeding?

Pregnancy The safety of Enspryng during pregnancy has not been fully established. There are no adequate and well-controlled studies in pregnant women to determine if the drug poses a risk to the fetus. Animal studies involving monkeys did not show adverse effects on pregnancy or fetal development, but animal results do not always predict human response. If you are of childbearing potential, your healthcare provider may recommend using effective contraception during treatment and for at least 3 months after your last dose. If you become pregnant while taking Enspryng, you should inform your doctor right away. Breastfeeding It is unknown if Enspryng passes into breast milk or if it could affect a nursing baby. Because the potential for serious adverse reactions in a breastfed infant is unknown, you should discuss the risks and benefits of breastfeeding with your healthcare provider. The decision to breastfeed while using this medication should consider the clinical need for the drug and the health benefits of breastfeeding for the infant.

Q: What is the FDA approval status of Enspryng?

FDA Approval Status Enspryng (satralizumab-mwge) received FDA approval in August 2020. It is classified as an interleukin-6 (IL-6) receptor antagonist and was the first subcutaneous treatment approved for neuromyelitis optica spectrum disorder (NMOSD) that allows for self-administration at home. Approved Indications The medication is specifically approved for use in adult patients who have tested positive for the anti-aquaporin-4 (AQP4) antibody. It is not approved for patients who are AQP4 antibody negative. Regulatory Designations and Safety During the approval process, the FDA granted Enspryng Orphan Drug designation, which is a status given to drugs intended to treat rare diseases. There are currently no boxed warnings or Risk Evaluation and Mitigation Strategy (REMS) requirements associated with this drug. However, regulatory labeling includes warnings about the risk of serious infections and the need to monitor liver enzymes and neutrophil counts during treatment.

Question 1

What is Enspryng?

Accepted Answer

Enspryng is a humanized monoclonal antibody that acts as an interleukin-6 (IL-6) receptor antagonist. It is designed to target and block the activity of IL-6, a signaling protein in the body that is known to drive inflammation and immune system activity.

By interfering with this specific pathway, the medication helps to regulate the immune response. This mechanism is used to address the biological processes involved in certain autoimmune conditions.

Question 2

What is Enspryng used for?

Accepted Answer

Enspryng is used to treat neuromyelitis optica spectrum disorder.

Question 3

How does Enspryng work?

Accepted Answer

Mechanism of Action

Enspryng belongs to a class of drugs known as interleukin-6 (IL-6) receptor antagonists. It is a laboratory-made protein called a monoclonal antibody that is designed to recognize and attach to a specific target in the body.

The target for Enspryng is the IL-6 receptor. IL-6 is a naturally occurring protein that acts as a chemical messenger in the immune system. While IL-6 helps the body fight infections, having too much of it can lead to excessive inflammation and cause the immune system to attack the body's own healthy tissues.

Reducing Immune Attacks

In neuromyelitis optica spectrum disorder (NMOSD), the immune system attacks the optic nerves and the spinal cord. This often involves the production of harmful antibodies and significant inflammation. By blocking the IL-6 receptor, Enspryng prevents the IL-6 protein from triggering these inflammatory responses.

This process helps to:

Limit inflammation in the central nervous system.
Reduce the activity of immune cells that contribute to nerve damage.
Lower the frequency of disease relapses or attacks.

Enspryng is used specifically in adults who have a certain type of NMOSD where the body produces antibodies against a protein called aquaporin-4 (AQP4).

Question 4

What are the active ingredients in Enspryng?

Accepted Answer

The active ingredient in Enspryng is satralizumab.

Question 5

What are the side effects of Enspryng?

Accepted Answer

Common side effects of Enspryng may include:

upper respiratory tract infection
headache
joint pain

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Enspryng?

Accepted Answer

Enspryng belongs to the IL-6 receptor antagonist drug class.

Question 7

What is the dosage of Enspryng and how do I take it?

Accepted Answer

Administration Method

Enspryng is given as a subcutaneous injection, which means it is injected into the fatty tissue just under the skin. The injection is usually administered in the abdomen or the thigh. It is important to rotate the injection site with each dose and avoid areas where the skin is tender, bruised, red, or hard.

General Dosing Pattern

The treatment schedule generally begins with a loading phase, where several initial doses are given at specific intervals. After this initial phase is complete, the medication is transitioned to a maintenance schedule where it is administered at regular intervals to help manage the condition.

Self-Injection and Preparation

A healthcare provider may train a patient or caregiver to administer the injection at home. Before use, the medication should be removed from the refrigerator and allowed to reach room temperature naturally. The solution should be inspected for particles or discoloration before injecting, and the syringe should not be shaken.

Missed Doses

If a dose is missed, it should be administered as soon as possible. Do not wait until the next scheduled dose is due. Once the missed dose is taken, the regular dosing schedule should be resumed based on that new timing.

Question 8

Is Enspryng safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

The safety of Enspryng during pregnancy has not been fully established. There are no adequate and well-controlled studies in pregnant women to determine if the drug poses a risk to the fetus. Animal studies involving monkeys did not show adverse effects on pregnancy or fetal development, but animal results do not always predict human response.

If you are of childbearing potential, your healthcare provider may recommend using effective contraception during treatment and for at least 3 months after your last dose. If you become pregnant while taking Enspryng, you should inform your doctor right away.

Breastfeeding

It is unknown if Enspryng passes into breast milk or if it could affect a nursing baby. Because the potential for serious adverse reactions in a breastfed infant is unknown, you should discuss the risks and benefits of breastfeeding with your healthcare provider. The decision to breastfeed while using this medication should consider the clinical need for the drug and the health benefits of breastfeeding for the infant.

Question 9

What forms and strengths does Enspryng come in?

Accepted Answer

Enspryng is supplied as a sterile, preservative-free solution for subcutaneous injection. It is available in the following delivery format:

Single-dose prefilled syringe: A ready-to-use syringe intended for injection into the fatty tissue under the skin.

This medication is designed for single use. Each syringe should be disposed of after use, even if medication remains in the syringe.

Question 10

What is the FDA approval status of Enspryng?

Accepted Answer

FDA Approval Status

Enspryng (satralizumab-mwge) received FDA approval in August 2020. It is classified as an interleukin-6 (IL-6) receptor antagonist and was the first subcutaneous treatment approved for neuromyelitis optica spectrum disorder (NMOSD) that allows for self-administration at home.

Approved Indications

The medication is specifically approved for use in adult patients who have tested positive for the anti-aquaporin-4 (AQP4) antibody. It is not approved for patients who are AQP4 antibody negative.

Regulatory Designations and Safety

During the approval process, the FDA granted Enspryng Orphan Drug designation, which is a status given to drugs intended to treat rare diseases. There are currently no boxed warnings or Risk Evaluation and Mitigation Strategy (REMS) requirements associated with this drug. However, regulatory labeling includes warnings about the risk of serious infections and the need to monitor liver enzymes and neutrophil counts during treatment.

Question 11

What should I know about Enspryng and cost?

Accepted Answer

Factors Affecting Cost

Several factors can influence the total cost of Enspryng treatment:

Insurance Coverage: Your out-of-pocket expenses, such as copays or coinsurance, depend on your specific health insurance plan and its formulary.
Specialty Pharmacy: Enspryng is a specialty medication and is typically dispensed through specialty pharmacies rather than standard retail pharmacies.
Administration: While Enspryng is designed for subcutaneous injection and can be self-administered at home, costs may vary if it is administered by a healthcare professional in a clinic or office setting.

Generic and Biosimilar Status

Enspryng is a brand-name biologic medication. There are currently no biosimilar or generic versions available. Brand-name specialty drugs generally have higher costs because they lack competition from lower-cost alternatives.

Financial Assistance Programs

The manufacturer may offer support programs to help manage the cost of Enspryng. These options often include:

Copay Cards: Eligible patients with commercial insurance may be able to use copay cards to reduce their monthly out-of-pocket costs.
Patient Assistance Programs: Programs may be available for individuals who are uninsured or underinsured to help them access the medication at a lower cost or for free.

It is recommended to contact your insurance provider or the manufacturer directly to understand the specific costs and assistance options available for your situation.

Enspryng

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Enspryng

Hospitals.net Disclosure